A detailed history of Mitsubishi Ufj Kokusai Asset Management Co., Ltd. transactions in Novavax Inc stock. As of the latest transaction made, Mitsubishi Ufj Kokusai Asset Management Co., Ltd. holds 17,645 shares of NVAX stock, worth $149,453. This represents 0.0% of its overall portfolio holdings.

Number of Shares
17,645
Previous 19,311 8.63%
Holding current value
$149,453
Previous $244,000 9.02%
% of portfolio
0.0%
Previous 0.0%

Shares

13 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q3 2024

Nov 07, 2024

SELL
$10.71 - $17.11 $17,842 - $28,505
-1,666 Reduced 8.63%
17,645 $222,000
Q2 2024

Aug 12, 2024

SELL
$3.89 - $20.97 $85,257 - $459,599
-21,917 Reduced 53.16%
19,311 $244,000
Q1 2024

May 09, 2024

SELL
$3.76 - $6.02 $7,098 - $11,365
-1,888 Reduced 4.38%
41,228 $197,000
Q4 2023

Feb 08, 2024

BUY
$4.8 - $7.67 $12,398 - $19,811
2,583 Added 6.37%
43,116 $206,000
Q3 2023

Nov 07, 2023

BUY
$6.81 - $9.74 $27,546 - $39,398
4,045 Added 11.09%
40,533 $293,000
Q2 2023

Aug 09, 2023

BUY
$6.67 - $9.52 $158,105 - $225,662
23,704 Added 185.42%
36,488 $271,000
Q4 2022

Feb 07, 2023

BUY
$8.86 - $25.04 $77,206 - $218,198
8,714 Added 214.1%
12,784 $131,000
Q3 2022

Nov 01, 2022

BUY
$18.2 - $76.12 $618 - $2,588
34 Added 0.84%
4,070 $74,000
Q2 2022

Aug 04, 2022

SELL
$36.28 - $75.29 $510,604 - $1.06 Million
-14,074 Reduced 77.71%
4,036 $208,000
Q1 2022

May 09, 2022

SELL
$69.73 - $142.9 $21,407 - $43,870
-307 Reduced 1.67%
18,110 $1.33 Million
Q4 2021

Feb 07, 2022

SELL
$134.56 - $217.97 $5,516 - $8,936
-41 Reduced 0.22%
18,417 $2.63 Million
Q3 2021

Nov 04, 2021

BUY
$177.8 - $270.58 $231,140 - $351,754
1,300 Added 7.58%
18,458 $3.83 Million
Q2 2021

Aug 06, 2021

BUY
$121.0 - $257.67 $2.08 Million - $4.42 Million
17,158 New
17,158 $3.64 Million

Others Institutions Holding NVAX

About NOVAVAX INC


  • Ticker NVAX
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 78,215,104
  • Market Cap $662M
  • Description
  • Novavax, Inc., a biotechnology company, focuses on the discovery, development, and commercialization of vaccines to prevent serious infectious diseases and address health needs. The company's vaccine candidates include NVX-CoV2373, a coronavirus vaccine candidate that is in two Phase III trials, one Phase IIb trial, and one Phase I/II trial; Nan...
More about NVAX
Track This Portfolio

Track Mitsubishi Ufj Kokusai Asset Management Co., Ltd. Portfolio

Follow Mitsubishi Ufj Kokusai Asset Management Co., Ltd. and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Mitsubishi Ufj Kokusai Asset Management Co., Ltd., based on Form 13F filings with the SEC.

News

Stay updated on Mitsubishi Ufj Kokusai Asset Management Co., Ltd. with notifications on news.